[Study using a new ultrafiltration technic of Bence Jones protein in patients with paraproteinemia].

M. Borgno,E. Bono,A. Costamagna,B. Frea,A. Tizzani,C. Ricci

1974-11-01

Abstract:

What problem does this paper attempt to address?

Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

J. Jonklaas,K. Burman,Brian W Kim,A. Cappola,D. Cooper,A. Bianco,Anna M. Sawka,Francesco S Celi,M. Rosenthal,A. Bauer,R. Peeters

DOI: https://doi.org/10.1089/thy.2014.0028

IF: 6.506

2014-12-01

Thyroid

Abstract:BACKGROUND A number of recent advances in our understanding of thyroid physiology may shed light on why some patients feel unwell while taking levothyroxine monotherapy. The purpose of this task force was to review the goals of levothyroxine therapy, the optimal prescription of conventional levothyroxine therapy, the sources of dissatisfaction with levothyroxine therapy, the evidence on treatment alternatives, and the relevant knowledge gaps. We wished to determine whether there are sufficient new data generated by well-designed studies to provide reason to pursue such therapies and change the current standard of care. This document is intended to inform clinical decision-making on thyroid hormone replacement therapy; it is not a replacement for individualized clinical judgment. METHODS Task force members identified 24 questions relevant to the treatment of hypothyroidism. The clinical literature relating to each question was then reviewed. Clinical reviews were supplemented, when relevant, with related mechanistic and bench research literature reviews, performed by our team of translational scientists. Ethics reviews were provided, when relevant, by a bioethicist. The responses to questions were formatted, when possible, in the form of a formal clinical recommendation statement. When responses were not suitable for a formal clinical recommendation, a summary response statement without a formal clinical recommendation was developed. For clinical recommendations, the supporting evidence was appraised, and the strength of each clinical recommendation was assessed, using the American College of Physicians system. The final document was organized so that each topic is introduced with a question, followed by a formal clinical recommendation. Stakeholder input was received at a national meeting, with some subsequent refinement of the clinical questions addressed in the document. Consensus was achieved for all recommendations by the task force. RESULTS We reviewed the following therapeutic categories: (i) levothyroxine therapy, (ii) non-levothyroxine-based thyroid hormone therapies, and (iii) use of thyroid hormone analogs. The second category included thyroid extracts, synthetic combination therapy, triiodothyronine therapy, and compounded thyroid hormones. CONCLUSIONS We concluded that levothyroxine should remain the standard of care for treating hypothyroidism. We found no consistently strong evidence for the superiority of alternative preparations (e.g., levothyroxine-liothyronine combination therapy, or thyroid extract therapy, or others) over monotherapy with levothyroxine, in improving health outcomes. Some examples of future research needs include the development of superior biomarkers of euthyroidism to supplement thyrotropin measurements, mechanistic research on serum triiodothyronine levels (including effects of age and disease status, relationship with tissue concentrations, as well as potential therapeutic targeting), and long-term outcome clinical trials testing combination therapy or thyroid extracts (including subgroup effects). Additional research is also needed to develop thyroid hormone analogs with a favorable benefit to risk profile.

Medicine
A review of the safety of triiodothyronine in combination with levothyroxine for the management of hypothyroidism

Ulrike Gottwald-Hostalek,Yorki Tayrouz

DOI: https://doi.org/10.1080/03007995.2024.2435460

2024-12-05

Current Medical Research and Opinion

Abstract:There remains considerable interest in the therapeutic use of combinations of levothyroxine (LT4) and triiodothyronine (liothyronine, T3) in the management of hypothyroidism, especially where hypothyroid-like symptoms persist on optimised LT4 monotherapy. This interest appears to be increasing, despite the lack of consistent identification of clinical benefit in people with hypothyroidism in randomised trials going back two decades. Guidelines support an individualised trial of addition of T3 to LT4 for symptomatic patients on optimised LT4. A new generation of clinical trials seeks to address this issue, using thyroid-specific instruments to measure patient-reported outcomes, among other innovations. Safety is the other critical element of the therapeutic profile of a drug. In this article, we review the safety of treatment LT4 + T3, with an emphasis on side-effects suggestive of thyrotoxicosis (overtreatment with thyroid hormones). Randomised trials that evaluated LT4 + T3 did not raise clear or consistent safety issues with this treatment. This was despite the use of regimens with a lower ratio of LT4:T3 (usually 4–10:1) than recommended currently by clinical experts in the field. In addition, a real-world analysis of side-effects of a commercial LT4 + T3 treatment (LT4:T3 ratio 5:1) that were reported spontaneously to a pharmacovigilance database revealed a low rate of reports, both overall and with regard to symptoms possible reminiscent of thyrotoxicosis. Safety concerns regarding the possibility of iatrogenic thyrotoxicosis appear unlikely to limit the future guideline-driven therapeutic use of LT4:T3 combinations with a ratio of these ingredients of around 15:1.

medicine, general & internal, research & experimental
Preliminary Results of a Double-Blind Randomized Controlled Trial Evaluating the Cardiometabolic Effects of Levothyroxine and Liothyronine Compared to Levothyroxine with Placebo in Athyreotic Low-Risk Thyroid Cancer Patients

Bernadette Biondi,Martina Pucci,Gilda Pontieri,Pietro Formisano,Roberta Esposito

DOI: https://doi.org/10.1089/thy.2023.0135

IF: 6.506

Thyroid

Abstract:Background: Evidence is needed on the risks and benefits of combination therapy with levothyroxine (LT4)+liothyronine (LT3) for the treatment of hypothyroidism. Objective and Methods: We performed a randomized, double-blind placebo-controlled study to assess the effects of LT4+LT3 therapy versus LT4+placebo in a homogeneous group of athyreotic patients, without cardiovascular risk factors during long-term replacement monotherapy with LT4. The primary objective of the study was to assess the effects of combination LT4+LT3 therapy on heart rate, cardiac rhythm, and sensitive cardiovascular parameters of cardiac morphology and function by means of electrocardiography and Doppler echocardiography. The secondary objective of the study was to evaluate patient compliance, tolerability, and potential adverse events. Results: Thirty-eight patients with postsurgical hypothyroidism satisfying the inclusion criteria were selected from a group of 300 patients with low-risk thyroid cancer followed for a routine follow-up; they were randomized to receive LT4+LT3 or LT4+placebo. Twenty-four patients were evaluated after 1 year of treatment. All clinical and laboratory parameters were compared with the results obtained from 50 healthy euthyroid volunteers without comorbidities, matched for gender, age, physical activity, and lifestyle. Participants and clinicians remained blinded to the treatment allocation. After 1 year of combination therapy, a significant improvement in the diastolic function, evidenced by a significant reduction in the E/e' ratio (p = 0.046) and its positive trend over time, was observed in the LT4+LT3 group versus the LT4+placebo group. In addition, the univariate analyses showed a significant relationship between free triiodothyronine (fT3) levels (in pg/mL) with Δ of variation of the E/e' ratio in the LT4+LT3 group (standardized β coefficient = 0.603 [confidence interval: 0.001-1.248], p = 0.050) after combination therapy. No adverse events including tachycardia, arrhythmias, atrial fibrillation, or other important events occurred between the first administration and the end of the study. Conclusions: In this preliminary report, combination treatment with LT4+LT3 induced favorable changes in cardiovascular parameters of diastolic function without any adverse cardiovascular events. Trial Registration: EUDRACT number: 2017-001261-25.
Use of thyroid hormones in hypothyroid and euthyroid patients: A survey of members of the Endocrine Society of Australia

Nicole Lafontaine,Suzanne J. Brown,Petros Perros,Enrico Papini,Endre V. Nagy,Roberto Attanasio,Laszlo Hegedüs,John P. Walsh

DOI: https://doi.org/10.1111/cen.15049

2024-03-12

Clinical Endocrinology

Abstract:Objective Hypothyroidism is a common endocrine condition usually managed with levothyroxine (LT4). However, controversy remains around the use of liothyronine (LT3). We aimed to investigate the practices of Australian endocrinologists when managing patients with hypothyroidism, their use of LT3 + LT4 combination therapy and use of thyroid hormones in euthyroid patients. Design and Participants Members of the Endocrine Society of Australia (ESA) were invited to participate in an online questionnaire. Measurements We analysed questionnaires that had complete demographic data. Results Eighty‐seven questionnaires fulfilled the criteria. LT4 was used as first line treatment for hypothyroidism by all respondents. Only 45% reported that their patients were dispensed the brand of LT4 that they recommend. LT3 (alone or in combination) was prescribed by 44% in their clinical practice. Although 49% of respondents would consider LT3 + LT4 in patients with normal TSH who had ongoing symptoms of hypothyroidism, the inability of LT4 to restore normal physiology was ranked the least likely explanation for persistent symptoms and only 32% would consider it for themselves if they were diagnosed with hypothyroidism. The majority (55%), in accordance with evidence, would not prescribe thyroid hormone to euthyroid individuals but 39% would consider use in euthyroid female infertility with high levels of thyroid antibodies and 11% in euthyroid patients with a simple goitre growing over time. LT4 use in pregnancy was variable among members. Conclusions Australian endocrinologists mostly follow international guidelines when prescribing thyroid hormone therapy and many prescribe combination LT3 and LT4 therapy, particularly for patients who remain symptomatic on LT4 monotherapy. Prescribing practices are largely similar to other countries who have completed similar questionnaires.

endocrinology & metabolism
Treatment Preferences in Patients with Hypothyroidism: an Analysis of Eleven Randomized Controlled Trials

Fabyan Esberard de Lima Beltrão,Giulia Carvalhal,Daniele Carvalhal de Almeida Beltrão,Fabricia Elisabeth de Lima Beltrão,Miriam O Ribeiro,Matthew D Ettleson,Helton Estrela Ramos,Antonio C Bianco

DOI: https://doi.org/10.1210/clinem/dgae651

2024-09-18

Abstract:Introduction: Levothyroxine (L-T4) monotherapy is the standard of care for the treatment of hypothyroidism. A minority of the L-T4-treated patients remain symptomatic and report better outcomes with combination therapy that contains liothyronine (L-T3) or with desiccated thyroid extract (DTE). Goal: To assess patient preferences in the treatment of hypothyroidism. Methods: A systematic review, meta-analysis, meta-regression, and network meta-analysis (NMA) of randomized controlled trials (RCTs) comparing treatments for adults with hypothyroidism (L-T4 vs. L-T4+L-T3 or DTE). Searches were conducted in PubMed, Embase, and Cochrane databases up to April 10, 2024. Data extraction and quality assessment were independently performed by four researchers. Results: Eleven RCTs (eight cross-over studies) with a total of 1,135 patients were considered. Overall, 24% of patients preferred L-T4 versus 52 % who preferred L-T4+L-T3 or DTE; 24% had no preference. The meta-analysis confirmed the preference for combination therapy over L-T4 monotherapy (RR: 2.20, 95% CI: 1.38 to 3.52; p = 0.0009). Excluding four studies reduced the high heterogeneity (I2 = 81%) without affecting the results (RR: 1.97, 95% CI: 1.52 to 2.54; p < 0.00001; I2 = 24%). This preference profile remained when only crossover studies were considered (RR: 2.84, 95% CI: 1.50 to 5.39; p < 0.00001). Network meta-analysis confirmed the preference for DTE and L-T3+L-T4 versus L-T4 alone. Conclusion: Patients with hypothyroidism prefer combination therapy (L-T3+L-T4 or DTE) over L-T4 monotherapy. The strength of these findings justifies considering patient preferences in the setting of shared decision-making in the treatment of hypothyroidism.
[Prolonged syncopes with atypical symptoms simulating epilepsy; electro-clinical study].

B. Schott,J. Courjon

1957-12-05

Abstract:
Thyroid nodules: a review of current guidelines, practices, and prospects

H Gharib,E Papini,R Paschke

DOI: https://doi.org/10.1530/eje-08-0135

2008-11-01

European Journal of Endocrinology

Abstract:In 2006, two major society-sponsored guidelines and one major consensus statement for thyroid diagnosis and management were published by: the American Association of Clinical Endocrinologists/Associazione Medici Endocrinologi (AACE/AME); the American Thyroid Association (ATA); and the European Thyroid Association (ETA). A careful review of these guidelines reveals that despite many similarities, significant differences are also present, likely reflecting differences in practice patterns, interpretation of existing data, and availability of resources in different regions. The methodology of the guidelines is similar, but a few differences in the rating scale make a rapid comparison of the strength of both evidence and recommendations difficult for the use in current clinical practice. Some recommendations are based mostly on experts' opinion. Thus, a same recommendation may be based on a different evidence; on the other hand, sometimes the same evidence may induce a different recommendation. Therefore, efforts are needed to produce a few high-quality clinical studies to close the evidence gaps in the still controversial fields of thyroid disease and to create a joint task force of the most authoritative societies in the field of thyroid disease in order to reach a common document for clinical practice recommendations.

endocrinology & metabolism
Optimizing the treatment of hypothyroidism

Antonio C. Bianco,Peter N. Taylor

DOI: https://doi.org/10.1038/s41574-024-00989-7

2024-04-30

Nature Reviews Endocrinology

Abstract:Daily levothyroxine (LT4) is the standard of care for the treatment of hypothyroidism; however, a small number of patients experience residual symptoms of hypothyroidism. Guidelines indicate that a trial with LT4 and liothyronine (LT3) could be attempted once other conditions have been addressed or excluded. Even so, currently, treatment of hypothyroidism can still be suboptimal.

endocrinology & metabolism
Real-life practice of thyroid hormone use in hypothyroid and euthyroid patients: A detailed view from the THESIS questionnaire survey in France

Camille Buffet,Lisa Belin,Roberto Attanasio,Roberto Negro,Lazlo Hegedüs,Endre V Nagy,Enrico Papini,Petros Perros,Laurence Leenhardt

DOI: https://doi.org/10.1016/j.ando.2021.11.002

Abstract:Aim: To describe practices of French physicians regarding thyroid hormone therapy, focusing on available LT4 formulations. Material and methods: Members of the French Endocrine Society (FES) and affiliated societies (the Endocrine Tumor Group, French College of Teachers of Endocrinology, Diabetes and Metabolic Diseases and the Union of Endocrinology, Diabetology, Metabolic Diseases and Nutrition Specialists) were invited to participate in an online survey. Results: Five hundred and thirty four of the 2,094 persons contacted (25.5%) completed the survey and were included in the analysis. The vast majority (99.4%) reported that levothyroxine (LT4) is the treatment of choice for hypothyroidism. 7.1% and 14.2% of respondents respectively considered liothyronine (LT3) or a combination of LT4 and LT3 for the treatment of hypothyroidism, mainly when symptoms persisted despite achieving normal TSH concentrations with LT4 therapy. For 44% of respondents, thyroid hormone treatment is never indicated in euthyroid patients, while the remainder would consider treating euthyroid patients with a goiter growing over time (40.2%) and/or euthyroid women with positive anti-TPO antibodies and infertility (31.7%). LT4 tablets were the preferred LT4 formulation. A significant proportion of FES members expected no major clinical differences upon changing to formulations such as soft-gel capsules or liquid solutions, even in specific scenarios such as poor biochemical control or suspicion of malabsorption. Conclusion: The treatment of choice for hypothyroidism in France is LT4. LT3-based therapy is considered by some physicians in case of persistent symptoms of hypothyroidism despite normal TSH level. A significant proportion of respondents (66.0%) would consider treating euthyroid patients, contrary to the present state of knowledge. These outdated practices should be addressed by professional bodies such as the FES.
[Airways and lung disease by metal working fluids].

D. Olten,M. Korn,T. Mensing,T. Brüning,R. Merget

Pneumologie

Abstract:Metal working fluids (MWF) are used in the manufacturing process to cool and lubricate machined parts. MWF contain the coolant, mostly water-oil emulsions with soluble semi-synthetic or synthetic oils, but also emulsifiers and additives. Reaction products and both bacterial and fungal contamination occur during use. In the present review we listed literature data of dose-effect-relationships with a focus on biological substances. Most studies describe obstructive airways disease due to irritant effects of MWF. Immunoglobulin E mediated airways disease or hypersensitivity pneumonitis have rarely been described. There is no doubt that MWF exert adverse effects on human airways, but there is few data concerning dose-effect relationships. The role of bacterial and fungal contamination or endotoxin exposure cannot be defined by the available information. However, there is some evidence that biological components in MWF may represent the most hazardous substances.
Clinical comparative efficacy and therapeutic strategies for the Hashimoto's thyroiditis: A systematic review and network meta-analysis

Jinli Luo,Ling Zhou,Aru Sun,Ye Min,Yiqun Lin,Lin Han

DOI: https://doi.org/10.1016/j.heliyon.2024.e35114

IF: 3.776

2024-07-31

Heliyon

Abstract:Ethnopharmacological relevance: Vitamin D (VD), selenium preparations (Se), and thyroid hormone replacement therapy are commonly used to treat Hashimoto thyroiditis (HT). Increasing evidence suggests that traditional Chinese medicine (TCM) is an effective therapeutic strategy in the treatment of HT. Aim of the study: This study aimed to investigate the efficacy and safety of commonly-used drugs for HT. Materials and methods: A literature search was performed using PubMed, Web of Science, Cochrane Library, EMBASE, Chinese China National Knowledge Infrastructure (CNKI), Clinical Trial Registry (Chi CTR), China Science and Technology Journal Database (the VIP), Wanfang Database, and China Chinese Biomedical Database (CBM) from January 1, 2003, to December 31, 2022. The outcomes included TPOAb, TgAb, TSH, FT3, FT4, and adverse events. Our study was registered in PROSPERO (CRD42023449705). Results: Sixty trials and 4719 participants were included, comparing 16 treatments: VD, Se, LT-4, Se + LT-4, HM, placebo + LT-4, HM + LT-4, Se + myolnositol, Se + VD, HM + Se, mannan peptide, LT-4+prednisone, Methimazole, Methimazole + HM, Tapazole + Propranolol, and placebo. We found that Chinese herbal medicine has significant effect vs. LT-4 [MD 0.10, 95 % confidence interval 0.02 to 0.50]) and LT-4+placebo [MD 0.10, 95 % confidence interval 0.01 to 0.77]) in reducing TPOAb. Although receiving LT-4+prednisone was not statistically significant, the treatment ranking showed that this combination therapy had the highest probability of reducing TPOAb levels (72.8 %). In addition, the effect of Se plus LT-4 was not statistically significant; however, the treatment ranking showed that this combination therapy had the highest probability (78.6 %) of reducing TgAb levels, followed by HM (64.0 %). Reports on side effects have mainly focused on the digestive and cardiovascular systems. Conclusion: Our analyses showed that HM alone or in combination with other treatments for patients with HT can improve the side effects of other drugs, enhance efficacy, and maybe the most effective option for treating HT. However, there still need further verified using high-quality evidence.
Use of levothyroxine for euthyroid, thyroid antibody positive women with infertility: Analyses of aggregate data from a survey of European thyroid specialists (Treatment of Hypothyroidism in Europe by Specialists: An International Survey)

Roberto Negro,Miloš Žarković,Roberto Attanasio,Laszlo Hegedüs,Endre V. Nagy,Enrico Papini,Ersin Akarsu,Maria Alevizaki,Göksun Ayvaz,Tomasz Bednarczuk,Biljana Nedeljković Beleslin,Eszter Berta,Miklos Bodor,Anna Maria Borissova,Mihail Boyanov,Camille Buffet,Maria‐Cristina Burlacu,Jamina Ćirić,Chagit Adler Cohen,Juan J. Díez,Harald Dobnig,Valentin Fadeyev,Benjamin C. T. Field,Eric Fliers,Dagmar Führer,Juan C. Galofré,Tommi Hakala,Jiskra Jan,Peter Kopp,Michael Krebs,Michal Kršek,Martin Kužma,Laurence Leenhardt,Vitaliy Luchytskiy,Francisca Marques Puga,Anne McGowan,Miguel Melo,Saara Metso,Carla Moran,Tatyana Morgunova,Dan Alexandru Niculescu,Božidar Perić,Tereza Planck,Catalina Poiana,Eyal Robenshtok,Patrick Olivier Rosselet,Marek Ruchala,Kamilla Ryom Riis,Alla Shepelkevich,Mykola Tronko,David Unuane,Irfan Vardarli,Edward Visser,Andromachi Vryonidou,Younes R. Younes,Petros Perros

DOI: https://doi.org/10.1111/cen.15099

2024-06-12

Clinical Endocrinology

Abstract:Objectives The use of levothyroxine (LT4) treatment aiming to improve fertility in euthyroid women with positive thyroid peroxidase antibodies (TPOAb) is not supported by the available evidence. The aim of the study was to document the use of LT4 by European thyroid specialists in such patients. Design The data presented derive from Treatment of Hypothyroidism in Europe by Specialists, an International Survey (THESIS), a questionnaire conducted between 2019 and 2021 to document the management of hypothyroidism by European thyroid specialists. Here, we report the aggregate results on the use of LT4 in infertile, euthyroid women with positive TPOAb. Results A total of 2316/5406 (42.8%) respondents stated that LT4 may be indicated in TPOAb positive euthyroid women with infertility. The proportion of those replying positively to this question varied widely across different countries (median 39.4, range 22.9%–83.7%). In multivariate analyses males (OR: 0.8; CI: 0.7–0.9) and respondents >60 years (OR: 0.7; 0.6–0.8) were the least inclined to consider LT4 for this indication. Conversely, respondents managing many thyroid patients ("weekly" [OR: 1.4; CI: 1.0–1.9], "daily" [OR: 1.8; CI: 1.3–2.4]) and practicing in Eastern Europe (OR: 1.5; CI: 1.3–1.9) were most likely to consider LT4. Conclusions A remarkably high number of respondents surveyed between 2019 and 2021, would consider LT4 treatment in TPOAb positive euthyroid women with infertility. This view varied widely across countries and correlated with sex, age and workload, potentially influencing patient management. These results raise concerns about potential risks of overtreatment.

endocrinology & metabolism
Difference in vector competence of two species of sympatric ticks, Amblyomma variegatum and Rhipicephalus appendiculatus, for Dugbe virus (Nairovirus, Bunyaviridae).

G. Steele,P. Nuttall

DOI: https://doi.org/10.1016/0168-1702(89)90071-3

IF: 6.286

1989-09-01

Virus Research

Abstract:
Liothyronine (LT3) prescribing in England: Are cost constraints inhibiting guideline implementation?

Heald AH,Premawardhana LD,Taylor PN,Dasha Depesina,Nadia Chaudhury,Okosieme OE,Stedman M,Dayan CM

DOI: https://doi.org/10.1111/cen.15061

2024-05-18

Clinical Endocrinology

Abstract:Background Primary hypothyroidism affects about 3% of the general population in Europe. In most cases people with hypothyroidism are treated with levothyroxine. In the context of the 2023 British Thyroid Association guidance and the 2020 Competitions and Marketing Authority (CMA) ruling, we examined prescribing data for levothyroxine, Natural desiccated thyroid (NDT) and liothyronine by dose, regarding changes over the years 2016–2022. Design Monthly primary care prescribing data for each British National Formulary code were analysed for levothyroxine, liothyronine and NDT. Patients and Measurements The rolling 12‐month total/average of cost or prescribing volume was used to identify the moment of change. Results included number of prescriptions, the actual costs, and the cost/prescription/mcg of drug. Results Liothyronine: In 2016 94% of the total 74,500 prescriptions were of the 20 mcg dose. In 2020 the percentage prescribed in the 5 mcg and 10 mcg doses started to increase so that by 2022 each reached nearly 27% of total liothyronine prescribing. The average cost/prescription in 2016 of 20 mcg was £404/prescription and this fell by 80% to £101 in 2022; while the 10 mcg cost of £348/prescription fell by only 35% to £255 and the 5 mcg cost of £355/prescription fell by 38% to £242/prescription. The total prescriptions of liothyronine in 2016 were 74,605, falling by 30% up to 2019 when they started to grow again ‐ most recently at 60,990−15% lower than the 2016 figure, with the result that total costs fell by 70% to £9 m/year. Conclusions Liothyronine costs fell after the CMA ruling but remain orders of magnitude higher than for levothyroxine. The remaining 0.2% of patients with liothyronine treated hypothyroidism are still absorbing 16% of medication costs. The lower liothyronine 5cmg and 10 mcg doses as recommended by BTA are 240% the costs of the 20 mcg dose. Thus, following latest BTA guidance which recommends the lower liothyronine doses still incurs substantial additional costs vs the prescribing liothyronine in the no longer recommended treatment regime. High drug price continues to impact clinical decisions, potentially limiting liothyronine therapy availability to a considerable number of patients who could benefit from this treatment.

endocrinology & metabolism
Use of thyroid hormone in hypothyroid patients and euthyroid subjects in Spain: A THESIS* questionnaire survey

Juan C Galofré,Roberto Attanasio,Laszlo Hegedüs,Endre Nagy,Roberto Negro,Enrico Papini,Petros Perros,Juan J Díez

DOI: https://doi.org/10.1016/j.endien.2022.07.001

Abstract:Background: Hypothyroidism is one of the leading conditions in endocrinology. Despite that fact, clinical indications for treatment still vary among Spanish specialists. Aims: To identify attitudes of Spanish specialists relating to the use of levothyroxine (LT4) and the management of hypothyroidism. Methods: The members of the Sociedad Española de Endocrinología y Nutrición (Spanish Society of Endocrinology and Nutrition) were invited to participate in a web-based survey. The survey, initially in English, was modified to reflect in accordance with the availability of thyroid hormone formulations in Spain. Results: A total of 505 of 1956 (25.8%) members (66% female) completed the survey; 97.4% declared that LT4 is the first-line therapy for hypothyroidism. The indications for LT4 therapy in euthyroidism were infertility in thyroid antibody-positive women (48.5%) and simple goitre (21.2%). However, 44.2% of specialists reported that there was no indication for LT4 therapy in such patients. Only a minority of respondents (2.6%) considered combining LT4 with liothyronine as the treatment of choice from inception, whereas 49% stated that it should never be used. Conclusions: The standard of treatment of hypothyroidism in Spain is almost exclusively with LT4 tablets. Availability of other formulations of LT4 or combination therapy for hypothyroidism management remains to be explored, especially in patients with persistent symptoms. Notably, non-evidence-based use of LT4 is widely practiced in Spain for euthyroid women with autoimmune thyroiditis and fertility issues.
Heterosis among closed lines of Hereford cattle. III. Postweaning growth and carcass traits in steers.

D. Anderson,D. D. Kress,P. Burfening,R. L. Blackwell

DOI: https://doi.org/10.2527/JAS1986.624950X

1986-04-01

Journal of Animal Science

Abstract:Feedlot and carcass characteristics of 276 steers from five closed lines of Hereford cattle and reciprocal crosses among these lines were studied. The traits studied were initial weight, final weight, 224-d gain, days on test, hot carcass weight, marbling score, longissimus muscle area, fat thickness, yield grade, dressing percentage and shear force. Year of record was a significant source of variation for most traits. Age of dam was a significant source of variation for growth traits but not carcass traits. Line of sire affected initial weight, final weight, 224-d gain, days on test, marbling score and dressing percentage. Significant heterosis was observed only for hot carcass weight. Heterosis estimates were 1.9% for initial weight, 2.2% for final weight, 2.5% for 224-d gain, -2.1% for days on test, .6% for hot carcass weight, -.6% for marbling score, 0 for carcass grade, .6% for longissimus muscle area, 2.3% for backfat thickness, .9% for yield grade, -.9% for dressing percent and -10.9% for shear force. Initial age on test affected only hot carcass weight. Hot carcass weight, dressing percentage, marbling score, longissimus muscle area and fat thickness were affected by slaughter weight. Slaughter age affected dressing percent and marbling score.
Recent Advances in Thyroid Hormone Regulation: Toward a New Paradigm for Optimal Diagnosis and Treatment

Rudolf Hoermann,John E. M. Midgley,Rolf Larisch,Johannes W. Dietrich

DOI: https://doi.org/10.3389/fendo.2017.00364

IF: 6.055

2017-12-22

Frontiers in Endocrinology

Abstract:In thyroid health, the pituitary hormone thyroid-stimulating hormone (TSH) raises glandular thyroid hormone production to a physiological level and enhances formation and conversion of T4 to the biologically more active T3. Overstimulation is limited by negative feedback control. In equilibrium defining the euthyroid state, the relationship between TSH and FT4 expresses clusters of genetically determined, interlocked TSH-FT4 pairs, which invalidates their statistical correlation within the euthyroid range. Appropriate reactions to internal or external challenges are defined by unique solutions and homeostatic equilibria. Permissible variations in an individual are much more closely constrained than over a population. Current diagnostic definitions of subclinical thyroid dysfunction are laboratory based, and do not concur with treatment recommendations. An appropriate TSH level is a homeostatic concept that cannot be reduced to a fixed range consideration. The control mode may shift from feedback to tracking where TSH becomes positively, rather than inversely related with FT4. This is obvious in pituitary disease and severe non-thyroid illness, but extends to other prevalent conditions including aging, obesity, and levothyroxine (LT4) treatment. Treatment targets must both be individualized and respect altered equilibria on LT4. To avoid amalgamation bias, clinically meaningful stratification is required in epidemiological studies. In conclusion, pituitary TSH cannot be readily interpreted as a sensitive mirror image of thyroid function because the negative TSH-FT4 correlation is frequently broken, even inverted, by common conditions. The interrelationships between TSH and thyroid hormones and the interlocking elements of the control system are individual, dynamic, and adaptive. This demands a paradigm shift of its diagnostic use.

endocrinology & metabolism
Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association

Jeffrey R. Garber,Rhoda H. Cobin,Hossein Gharib,James V. Hennessey,Irwin Klein,Jeffrey I. Mechanick,Rachel Pessah-Pollack,Peter A. Singer,Kenneth A. Woeber for the American Association

DOI: https://doi.org/10.1089/thy.2012.0205

IF: 6.506

2012-12-01

Thyroid

Abstract:BACKGROUND: Hypothyroidism has multiple etiologies and manifestations. Appropriate treatment requires an accurate diagnosis and is influenced by coexisting medical conditions. This paper describes evidence-based clinical guidelines for the clinical management of hypothyroidism in ambulatory patients.METHODS: The development of these guidelines was commissioned by the American Association of Clinical Endocrinologists (AACE) in association with American Thyroid Association (ATA). AACE and the ATA assembled a task force of expert clinicians who authored this article. The authors examined relevant literature and took an evidence-based medicine approach that incorporated their knowledge and experience to develop a series of specific recommendations and the rationale for these recommendations. The strength of the recommendations and the quality of evidence supporting each was rated according to the approach outlined in the American Association of Clinical Endocrinologists Protocol for Standardized Production of Clinical Guidelines-2010 update.RESULTS: Topics addressed include the etiology, epidemiology, clinical and laboratory evaluation, management, and consequences of hypothyroidism. Screening, treatment of subclinical hypothyroidism, pregnancy, and areas for future research are also covered.CONCLUSIONS: Fifty-two evidence-based recommendations and subrecommendations were developed to aid in the care of patients with hypothyroidism and to share what the authors believe is current, rational, and optimal medical practice for the diagnosis and care of hypothyroidism. A serum thyrotropin is the single best screening test for primary thyroid dysfunction for the vast majority of outpatient clinical situations. The standard treatment is replacement with L-thyroxine. The decision to treat subclinical hypothyroidism when the serum thyrotropin is less than 10 mIU/L should be tailored to the individual patient.

endocrinology & metabolism
Response to Fitzgerald et al. re: "Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status"

Tze Ping Loh,Joel Ehrenkranz,David Halsall,Kelly Hoff,Carole A. Spencer,Katleen Van Uytfanghe,Josef Köhrle,ATA Thyroid Function Tests Writing Group

DOI: https://doi.org/10.1089/thy.2023.0604

IF: 6.506

2024-01-19

Thyroid

Abstract:Dear Editor: W e thank Fitzgerald et al. 1 for their letter and their interest in the commissioned review. 2 We appreciate the authors' efforts in presenting alternative views on the use of thyrotropin (TSH) and free thyroxine (fT4) in the assessment of thyroid status in peripheral tissues. Specifically, Fitzgerald et al. propose that fT4 may be "the best single indicator of thyroid status of peripheral tissues" 1 and provide supporting statements on the superior correlation of fT4 with clinical outcomes. They also challenge the assumption of a log–linear relationship between TSH and fT4, highlight that TSH is susceptible to change in nonthyroidal conditions, and that individual thyroid set points may be lacking.

endocrinology & metabolism
Therapeutic efficacy and patient compliance of levothyroxine liquid and softgel formulations taken with meals: a systematic review

Vittorio Oteri,Salvatore Volpe,Mariarita Lopes,Giulia Sceusa,Andrea Tumminia,Antonino Belfiore,Francesco Frasca,Damiano Gullo

DOI: https://doi.org/10.1007/s12020-024-04016-7

2024-08-31

Endocrine

Abstract:Purpose: Levothyroxine (L-T4) is the drug of choice for treating primary hypothyroidism. L-T4 tablets should be taken at least 30 min before breakfast. Several studies have suggested that serum thyroid profile is not affected by concomitant intake of liquid/softgel L-T4 with meals. Our aim is to review the evidence on therapeutic efficacy and patient compliance with the liquid and softgel formulation of L-T4 taken with meals, also compared with the standard tablet therapy regimen, in hypothyroid patients. Methods: We performed a systematic review of literature by searching PubMed, Embase, and Cochrane Library databases. PRISMA guidelines were applied, and the risk of bias of the included studies was assessed using the RoB 2 and ROBINS tools. The methodological quality was assessed following the GRADE criteria. Results: We included 13 studies, accounting for a total of 1697 patients. The timing of liquid L-T4 intake from breakfast did not affect the therapeutic efficacy of the treatment. No significant differences in the absorption of liquid L-T4 were found when administered together with different foods, beverages, drugs, or other supplements. TSH levels are not influenced by taking softgel L-T4 at breakfast; the efficacy of softgel and liquid formulation is similar when they are taken with a meal, but superior to that of tablet formulation. Shifting from L-T4 tablets taken 30 min before breakfast to liquid/softgel formulation taken with the meal improved medication adherence and perceived quality of life of patients. Conclusion: Liquid and softgel formulation of L-T4 can be taken at breakfast or close to meals, without losing therapeutic efficacy. These formulations could also improve patient compliance and quality of life compared to L-T4 tablet therapy taken 30 min before breakfast.

[Study using a new ultrafiltration technic of Bence Jones protein in patients with paraproteinemia].

Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

A review of the safety of triiodothyronine in combination with levothyroxine for the management of hypothyroidism

Preliminary Results of a Double-Blind Randomized Controlled Trial Evaluating the Cardiometabolic Effects of Levothyroxine and Liothyronine Compared to Levothyroxine with Placebo in Athyreotic Low-Risk Thyroid Cancer Patients

Use of thyroid hormones in hypothyroid and euthyroid patients: A survey of members of the Endocrine Society of Australia

Treatment Preferences in Patients with Hypothyroidism: an Analysis of Eleven Randomized Controlled Trials

[Prolonged syncopes with atypical symptoms simulating epilepsy; electro-clinical study].

Thyroid nodules: a review of current guidelines, practices, and prospects

Optimizing the treatment of hypothyroidism

Real-life practice of thyroid hormone use in hypothyroid and euthyroid patients: A detailed view from the THESIS questionnaire survey in France

[Airways and lung disease by metal working fluids].

Clinical comparative efficacy and therapeutic strategies for the Hashimoto's thyroiditis: A systematic review and network meta-analysis

Use of levothyroxine for euthyroid, thyroid antibody positive women with infertility: Analyses of aggregate data from a survey of European thyroid specialists (Treatment of Hypothyroidism in Europe by Specialists: An International Survey)

Difference in vector competence of two species of sympatric ticks, Amblyomma variegatum and Rhipicephalus appendiculatus, for Dugbe virus (Nairovirus, Bunyaviridae).

Liothyronine (LT3) prescribing in England: Are cost constraints inhibiting guideline implementation?

Use of thyroid hormone in hypothyroid patients and euthyroid subjects in Spain: A THESIS* questionnaire survey

Heterosis among closed lines of Hereford cattle. III. Postweaning growth and carcass traits in steers.

Recent Advances in Thyroid Hormone Regulation: Toward a New Paradigm for Optimal Diagnosis and Treatment

Clinical Practice Guidelines for Hypothyroidism in Adults: Cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association

Response to Fitzgerald et al. re: "Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status"

Therapeutic efficacy and patient compliance of levothyroxine liquid and softgel formulations taken with meals: a systematic review